Next Steps - from the 3Q2016 Corporate PresentationThis is from the
3Q2016 Corporate Presentation I have added one quarter to each item, because of the delay, and hope this is now accurate:
Pending: 4Q2016 - Health Canada Investigational Testing Authorization (“ITA”) Approval and commence enrolling patients into Health Canada Phase Ib clinical study for NMIBC
1Q2017 - FDA pre-Investigational New Drug Application (“IND”) Approval for NMIBC
2Q2017 - Commence enrolling patients into Health Canada Phase Ib clinical study for brain cancer and commence enrolling patients into FDA Phase Ib clinical study for lung cancer
3Q2017 - Complete Health Canada Phase Ib clinical study for NMIBC
4Q2017 - Commence enrolling subjects into Health Canada / FDA / CE Phase IIb clinical study for NMIBC
1Q2018 - FDA pre-Investigational New Drug Application (“IND”) Approval for lung and brain cancer
1Q2018 - Complete Health Canada Phase Ib clinical study for brain cancer and FDA Phase Ib clinical study for lung cancer
2Q2018 - Commence enrolling patients into Health Canada / FDA / CE Phase Ib clinical study for brain cancer and lung cancer
3Q2019 - Complete Health Canada / FDA / CE Phase IIb clinical study for NMIBC
1Q2021 - Complete Health Canada / FDA / CE Phase Ib clinical study for brain cancer and lung cancer